Akebia (NASDAQ: AKBA) investor plans 84,829-share Rule 144 stock sale

Rhea-AI Filing Summary

Akebia Therapeutics, Inc. shareholder plans to sell common stock under Rule 144. The notice covers the proposed sale of 84,829 shares of Akebia common stock, with an aggregate market value of $118,294.00. The shares are to be sold through Morgan Stanley Smith Barney LLC on the Nasdaq market, with an approximate sale date of February 2, 2026.

The securities were acquired as restricted stock from Akebia Therapeutics, Inc. on January 31, 2026, with 84,829 shares granted and payment noted as non-cash. The filing also notes total shares outstanding of 265,365,993 common shares, providing context for the size of the proposed sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	84829	118294.00	265365993	02/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/31/2026	Restricted Stock	Akebia Therapeutics, Inc.			84829	02/02/2026	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Akebia (AKBA) Rule 144 filing disclose?

The filing discloses a planned sale of 84,829 Akebia common shares under Rule 144. These shares have an aggregate market value of $118,294.00 and are to be sold on Nasdaq through Morgan Stanley Smith Barney LLC, subject to Rule 144 conditions.

How many Akebia (AKBA) shares are planned to be sold and on which exchange?

The notice covers a planned sale of 84,829 common shares of Akebia Therapeutics, Inc. stock. The securities are listed for sale on the Nasdaq exchange, with Morgan Stanley Smith Barney LLC acting as the broker for the transaction.

What is the market value of Akebia (AKBA) shares in this Rule 144 sale?

The planned Rule 144 sale involves Akebia common stock with an aggregate market value of $118,294.00. This value is tied to the 84,829 shares indicated in the filing, reflecting the approximate market price at the time the notice was prepared.

When were the Akebia (AKBA) shares acquired and in what form?

The 84,829 Akebia shares were acquired on January 31, 2026 as restricted stock from Akebia Therapeutics, Inc. The filing identifies the issuer as the source and notes the nature of the acquisition transaction as a restricted stock grant rather than a cash purchase.

What is the approximate date of sale in the Akebia (AKBA) Rule 144 notice?

The Rule 144 notice lists an approximate date of sale of February 2, 2026 for the 84,829 Akebia common shares. This date reflects when the holder expects to begin selling the securities on Nasdaq through Morgan Stanley Smith Barney LLC.

How many Akebia (AKBA) shares are outstanding compared to the planned sale?

The filing reports 265,365,993 Akebia common shares outstanding. The planned Rule 144 sale covers 84,829 shares. This outstanding share count provides context for the relative size of the proposed sale versus the company’s total common stock base.